

**Supplementary Table 6.** Prevalence of *MET* tyrosine kinase domain (TKD) mutations across cancer types in cohort #1.

Cancer Type	Oncogenic / likely oncogenic <i>MET</i> TKD mutations (N)	Oncogenic / likely oncogenic <i>MET</i> TKD mutations (%)	<i>MET</i> TKD mutations of unknown biological function (N)	<i>MET</i> TKD mutations of unknown biological function (%)	Total <i>MET</i> TKD mutations (N)	Total <i>MET</i> TKD mutations (%)	Total (N)
Melanoma	7	0.12	82	1.39	89	1.50	5,916
Renal Cancer	34	1.05	9	0.28	43	1.33	3,226
Uterine Cancer	4	0.08	60	1.13	64	1.20	5,330
Other Skin Cancer	0	0	10	1.03	10	1.03	973
Neuroendocrine Cancer	0	0	7	0.78	8	0.90	893
SCLC	0	0	3	0.78	3	0.78	383
Colorectal Cancer	1	0.01	89	0.60	90	0.61	14,795
Bladder Cancer	1	0.03	17	0.52	18	0.55	3,246
NSCLC	44	0.19	76	0.33	120	0.52	23,195
CUP	2	0.17	4	0.34	6	0.51	1,184
GU Others	0	0	3	0.51	3	0.51	592
Head And Neck Cancer	0	0	12	0.47	12	0.47	2,536
Other Gynecologic Cancer	0	0	4	0.46	4	0.46	869
Brain Cancer	0	0	45	0.45	45	0.45	10,007
Gastric Cancer	1	0.04	8	0.35	9	0.40	2,266
Esophageal Cancer	2	0.06	9	0.27	11	0.34	3,280
GIST	1	0.08	3	0.24	4	0.32	1,236
Ovarian Cancer	2	0.03	16	0.26	18	0.29	6,105
Liver	1	0.05	5	0.24	6	0.29	2,042
Prostatic Cancer	0	0	12	0.25	12	0.25	4,827
Breast Cancer	0	0	30	0.24	30	0.24	12,375
Sarcoma	1	0.02	10	0.21	11	0.23	4,704
Biliary Tract Cancer	2	0.06	5	0.15	7	0.21	3,293
Other Cancers*	1	0.01	18	0.16	19	0.17	11,442
Pancreatic Cancer	1	0.02	8	0.14	9	0.16	5,676
Blood Cancer	0	0	12	0.15	12	0.15	8,135
Other GI Cancer	0	0	1	0.08	1	0.08	1,248

Abbreviations: CUP, cancer of unknown primary; SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; GU, genitourinary; GIST, gastrointestinal stromal tumors; GI, gastrointestinal; NOS, not otherwise specified. \*Other cancers are detailed in Supplementary Table 7.